These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23579458)

  • 1. Novel chemotherapeutic drugs in sphingolipid cancer research.
    Canals D; Hannun YA
    Handb Exp Pharmacol; 2013; (215):211-38. PubMed ID: 23579458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of sphingolipid metabolism enzymes.
    Delgado A; Casas J; Llebaria A; Abad JL; Fabrias G
    Biochim Biophys Acta; 2006 Dec; 1758(12):1957-77. PubMed ID: 17049336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicinal chemistry aspects of drug targets in sphingolipid metabolism.
    Nussbaumer P
    ChemMedChem; 2008 Apr; 3(4):543-51. PubMed ID: 18061920
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.
    Canals D; Perry DM; Jenkins RW; Hannun YA
    Br J Pharmacol; 2011 Jun; 163(4):694-712. PubMed ID: 21615386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid metabolizing enzymes as novel therapeutic targets.
    Billich A; Baumruker T
    Subcell Biochem; 2008; 49():487-522. PubMed ID: 18751924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingolipid modulation: a strategy for cancer therapy.
    Delgado A; Fabrias G; Bedia C; Casas J; Abad JL
    Anticancer Agents Med Chem; 2012 May; 12(4):285-302. PubMed ID: 21864240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids and response to chemotherapy.
    Dimanche-Boitrel MT; Rebillard A
    Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver.
    He Q; Suzuki H; Sharma N; Sharma RP
    Toxicol Sci; 2006 Dec; 94(2):388-97. PubMed ID: 16960033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice.
    Okuro RT; Machado MN; Casquilho NV; Jardim-Neto A; Roncally-Carvalho A; Atella GC; Zin WA
    Pulm Pharmacol Ther; 2018 Jun; 50():100-110. PubMed ID: 29702255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel drugs targeting sphingolipid metabolism.
    Bhabak KP; Arenz C
    Handb Exp Pharmacol; 2013; (215):187-96. PubMed ID: 23579456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic disorders of simple sphingolipid metabolism.
    Albinet V; Bats ML; Bedia C; Sabourdy F; Garcia V; Ségui B; Andrieu-Abadie N; Hornemann T; Levade T
    Handb Exp Pharmacol; 2013; (215):127-52. PubMed ID: 23579453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymes of sphingolipid metabolism in Drosophila melanogaster.
    Acharya U; Acharya JK
    Cell Mol Life Sci; 2005 Jan; 62(2):128-42. PubMed ID: 15666085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of ceramide analogs as potential anticancer agents.
    Liu J; Beckman BS; Foroozesh M
    Future Med Chem; 2013 Aug; 5(12):1405-21. PubMed ID: 23919551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa.
    Dany M; Elston D
    J Am Acad Dermatol; 2017 Aug; 77(2):268-273.e6. PubMed ID: 28551069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR.
    Aoyama Y; Sobue S; Mizutani N; Inoue C; Kawamoto Y; Nishizawa Y; Ichihara M; Kyogashima M; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2017 Apr; 486(2):551-557. PubMed ID: 28322796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and regulation of bioactive sphingolipids.
    Heffernan-Stroud LA; Obeid LM
    Adv Enzyme Regul; 2011; 51(1):219-28. PubMed ID: 21035490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models for studying the pathophysiology of ceramide.
    Kawamori T
    Adv Exp Med Biol; 2010; 688():109-17. PubMed ID: 20919649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhibitors of key enzymes of sphingolipid metabolism on insulin-induced glucose uptake and glycogen synthesis in liver cells of old rats.
    Babenko NA; Kharchenko VS
    Biochemistry (Mosc); 2015 Jan; 80(1):104-12. PubMed ID: 25754045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Development in the Field of Sphinogolipid Metabolism.
    Qu Z; Zhou L
    Adv Exp Med Biol; 2022; 1372():169-188. PubMed ID: 35503181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases.
    Sakamoto W; Canals D; Salamone S; Allopenna J; Clarke CJ; Snider J; Obeid LM; Hannun YA
    J Lipid Res; 2019 Nov; 60(11):1841-1850. PubMed ID: 31243119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.